Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Torrent Pharmaceuticals Ltd.

http://www.torrentpharma.com

Latest From Torrent Pharmaceuticals Ltd.

Tweak API Scheme For ‘Self-Reliant’ India, Says Industry

Companies including Dr Reddy’s will consider investing in new API units if the Indian government tweaks its incentive scheme to permit exports of surplus production. Other suggested changes to the $1.3bn stimulus, aimed at enhancing the country's medicines security, include extending incentives to brownfield expansions and removing restrictions on a change in product mix.

India Policy & Regulation

Working With Patients To Use AI Against Rare Diseases

Tim Guilliams, CEO of Healx, talks about the company’s mission of creating from existing drugs new options for rare disease patients. The company is using artificial intelligence to find combination treatments against rare conditions, while working closely with patient groups as key partners in the development process. The goal: faster development timelines and cheaper therapies for patients.

Artificial Intelligence C-Suite Speaks

Torrent Outlook Muted On COVID-19

After a tepid performance in the fiscal fourth quarter, Torrent expects its key markets India, US and Brazil to be impacted by the COVID-19 fallout as well as a lack of visibility on regulatory approvals for its manufacturing facilities.

Strategy Sales & Earnings

Torrent Outlook Muted On COVID-19, Regulatory Concerns

After a tepid performance in the fiscal fourth quarter, Torrent expects its key markets India, US and Brazil to be impacted by the COVID-19 fallout as well as a lack of visibility on regulatory approvals for its manufacturing facilities.

Commercial Sales & Earnings
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Distributors
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Unichem Laboratories Ltd.
    • Bio-Pharm, Inc.
UsernamePublicRestriction

Register